Jeff is a 60-year-old patient with myeloproliferative disease. After his care team secured a 9/10 match, he received an allogeneic hematopoietic stem cell transplantation with a conditioning regimen of fludarabine and melphalan. Neutrophil engraftment occurred at day 20, and he was discharged to home shortly after engraftment. One month later, he presented to the clinic with abdominal pain and a new diffuse erythematous rash, which his care team initially treated with corticosteroids.
Nine Oncology Nursing Society (ONS) members were included among the highly distinguished nurse leaders inducted into the American Academy of Nursing’s (AAN’s) 2021 Class of Fellows. In total, 225 inductees will be recognized at the Academy’s annual conference, taking place on October 7–9, 2021, virtually and in-person in Washington, DC.
On August 19, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk for recurrence after undergoing radical resection.
The negative stigma surrounding HIV can affect patients’ emotional well-being and mental health, and the stigma can come from anywhere: healthcare professionals, communities, and even themselves. In partnership with the Office of the Assistant Secretary of Health and Office of Infectious Disease and HIV/AIDS Policy, the U.S.
Nurses’ skills, experiences, leadership, and voices are more relevant than ever before, and more and more ONS members are sharing their knowledge and expertise beyond the bedside to improve health throughout the community.
The COVID-19 coronavirus pandemic has shed light on the U.S. healthcare system’s wide range of issues, from accessibility to barriers and social determinants of health. The country must respond with strategies to address future public health emergencies, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee said in an April 2021 letter.
On August 16, 2021, the U.S. Food and Drug Administration (FDA) reported Pfizer’s voluntary recall of an additional four lots of varenicline 0.5mg/1 mg tablets to the patient level because of the presence of N-nitroso-varenicline, a nitrosamine, above the Pfizer-established acceptable daily intake level. To date, Pfizer has not received any reports of adverse events that have been related to the recall. FDA reported Pfizer’s recall of 12 lots of varenicline tablets because of N-nitroso varenicline content on July 19, 2021.
Nursing has long been associated with healing hands. Laying hands on patients’ bodies is personal and intimate, providing comfort, soothing reassurance, strength, and hope. It builds a sacred trust that engenders care. When that foundational element of nursing was removed to follow social distancing protocols during the COVID-19 coronavirus pandemic, nurses found a new avenue to connect with their patients—through the use of telehealth.
Evolution may be the key to understanding immunity—or at least the National Institutes of Health (NIH) thinks so. Studies of the history of human life could uncover discoveries that have implications for all types of disease, including cancer.
On August 17, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab-gxly (Jemperli®) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.